182 related articles for article (PubMed ID: 38053165)
21. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
Boukerroucha M; Josse C; ElGuendi S; Boujemla B; Frères P; Marée R; Wenric S; Segers K; Collignon J; Jerusalem G; Bours V
BMC Cancer; 2015 Oct; 15():755. PubMed ID: 26490435
[TBL] [Abstract][Full Text] [Related]
23. Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
Felicio PS; Melendez ME; Arantes LM; Kerr LM; Carraro DM; Grasel RS; Campacci N; Scapulatempo-Neto C; Fernandes GC; de Carvalho AC; Palmero EI
Oncotarget; 2017 Jan; 8(2):2850-2862. PubMed ID: 27926510
[TBL] [Abstract][Full Text] [Related]
24. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Xu Y; Diao L; Chen Y; Liu Y; Wang C; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Deng D; Narod SA; Xie Y
Ann Oncol; 2013 Jun; 24(6):1498-505. PubMed ID: 23406733
[TBL] [Abstract][Full Text] [Related]
25. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
27. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
Stefansson OA; Jonasson JG; Olafsdottir K; Hilmarsdottir H; Olafsdottir G; Esteller M; Johannsson OT; Eyfjord JE
Epigenetics; 2011 May; 6(5):638-49. PubMed ID: 21593597
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
[TBL] [Abstract][Full Text] [Related]
29. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
Daniels SL; Burghel GJ; Chambers P; Al-Baba S; Connley DD; Brock IW; Cramp HE; Dotsenko O; Wilks O; Wyld L; Cross SS; Cox A
PLoS One; 2016; 11(7):e0160174. PubMed ID: 27463681
[TBL] [Abstract][Full Text] [Related]
30. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
31. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
32. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer.
Wong EM; Southey MC; Fox SB; Brown MA; Dowty JG; Jenkins MA; Giles GG; Hopper JL; Dobrovic A
Cancer Prev Res (Phila); 2011 Jan; 4(1):23-33. PubMed ID: 20978112
[TBL] [Abstract][Full Text] [Related]
33. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
34. Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Hsu NC; Huang YF; Yokoyama KK; Chu PY; Chen FM; Hou MF
PLoS One; 2013; 8(2):e56256. PubMed ID: 23405268
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
Glodzik D; Bosch A; Hartman J; Aine M; Vallon-Christersson J; Reuterswärd C; Karlsson A; Mitra S; Niméus E; Holm K; Häkkinen J; Hegardt C; Saal LH; Larsson C; Malmberg M; Rydén L; Ehinger A; Loman N; Kvist A; Ehrencrona H; Nik-Zainal S; Borg Å; Staaf J
Nat Commun; 2020 Jul; 11(1):3747. PubMed ID: 32719340
[TBL] [Abstract][Full Text] [Related]
36. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
37. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
[TBL] [Abstract][Full Text] [Related]
38. Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Mahfoudh W; Bettaieb I; Ghedira R; Snoussi K; Bouzid N; Klayech Z; Gabbouj S; Remadi Y; Hassen E; Bouaouina N; Zakhama A
J Transl Med; 2019 Apr; 17(1):123. PubMed ID: 30975216
[TBL] [Abstract][Full Text] [Related]
39. Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
Fumagalli C; Pruneri G; Possanzini P; Manzotti M; Barile M; Feroce I; Colleoni M; Bonanni B; Maisonneuve P; Radice P; Viale G; Barberis M
Breast Cancer Res Treat; 2012 Jul; 134(1):131-7. PubMed ID: 22228432
[TBL] [Abstract][Full Text] [Related]
40. Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Arif T; Anwar N
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2395-2401. PubMed ID: 32856871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]